We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+14.07%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$20.9M
(+14%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
8.03%
Top 10 Holdings %
Top 10 Hldgs %
57.53%
Holding
45
New
15
Increased
6
Reduced
8
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$10.8M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$10.5M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$9.37M |
| 4 |
PTC Therapeutics
PTCT
|
+$8.87M |
| 5 |
Quanterix
QTRX
|
+$8.35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$12M |
| 2 |
Sotera Health
SHC
|
+$10.2M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$9.36M |
| 4 |
Adaptive Biotechnologies
ADPT
|
+$6.87M |
| 5 |
EPIX
ESSA Pharma
EPIX
|
+$6.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.56% |
| 2 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alkermes
ALKS
$8.11B
| $11.5M | 6.92% |
373,382
+68,137
| +22% | +$1.92M |
|
|
2
Medtronic
MDT
$112B
| $10.5M | 6.31% |
+83,737
| New | +$10.8M |
|
3
Insulet
PODD
$11.8B
| $10.4M | 6.28% |
36,732
+7,789
| +27% | +$2.22M |
|
|
HOLX
4
DELISTED
Hologic
HOLX
| $10.3M | 6.16% |
138,884
+92,700
| +201% | +$6.95M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $10.2M | 6.1% |
+229,117
| New | +$10.5M |
|
|
DICE
6
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $9.01M | 5.42% |
+275,165
| New | +$9.37M |
|
|
ARNA
7
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.93M | 5.37% |
150,001
+7,755
| +5% | +$458K |
|
8
Cytokinetics
CYTK
$10.6B
| $8.8M | 5.29% |
+246,336
| New | +$7.25M |
|
|
9
Quanterix
QTRX
$159M
| $8.06M | 4.85% |
+161,933
| New | +$8.35M |
|
|
10
PTC Therapeutics
PTCT
$6.18B
| $8.04M | 4.83% |
+215,985
| New | +$8.87M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.43M | 4.47% |
41,991
-15,988
| -28% | -$2.57M |
|
12
AstraZeneca
AZN
$269B
| $6.98M | 4.2% |
58,121
-29,884
| -34% | -$3.48M |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $6.59M | 3.96% |
+1,072,698
| New | +$4.07M |
|
|
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
| $6.25M | 3.75% |
653,976
+354,692
| +119% | +$3.63M |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.77M | 3.47% |
+355,396
| New | +$3.87M |
|
16
Kymera Therapeutics
KYMR
$8.66B
| $5.23M | 3.15% |
89,071
-34,292
| -28% | -$1.99M |
|
17
Baxter International
BAX
$12.8B
| $4.95M | 2.98% |
+61,570
| New | +$4.87M |
|
|
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.65M | 2.79% |
474,368
+74,592
| +19% | +$587K |
|
19
Aclaris Therapeutics
ACRS
$715M
| $4.35M | 2.62% |
241,701
-74,133
| -23% | -$1.19M |
|
20
Kura Oncology
KURA
$793M
| $3.64M | 2.19% |
+194,309
| New | +$3.66M |
|
|
RNAM
21
DELISTED
Avidity Biosciences
RNAM
| $3.11M | 1.87% |
+126,116
| New | +$2.74M |
|
22
PMV Pharmaceuticals
PMVP
$57.1M
| $3.01M | 1.81% |
100,882
-894
| -0.9% | -$28.5K |
|
|
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.73M | 1.64% |
+24,949
| New | +$2.59M |
|
|
ITOS
24
DELISTED
iTeos Therapeutics
ITOS
| $1.55M | 0.93% |
57,286
-3,962
| -6% | -$104K |
|
25
Avalo Therapeutics
AVTX
$1.01B
| $1.17M | 0.7% |
+186
| New | +$1.51M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Asymmetry Capital Management held 45 positions worth $166M, up 14% from $145M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Asymmetry Capital Management deployed $13.4M of net new capital in Q3 2021, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was Medtronic: 83,737 shares worth $10.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was AstraZeneca, an estimated $3.48M trimmed.
- Asymmetry Capital Management's largest Q3 2021 buy was Medtronic: 83,737 shares worth $10.5M.
- Asymmetry Capital Management added most to Hologic in Q3 2021, an estimated $6.95M increase.
- Asymmetry Capital Management's biggest Q3 2021 reduction was AstraZeneca, cutting an estimated $3.48M.
- Asymmetry Capital Management fully exited Centene in Q3 2021, selling an estimated $12M.
- Asymmetry Capital Management's ten largest holdings make up 58% of its $166M portfolio in Q3 2021.
- Asymmetry Capital Management opened 15 new positions and closed 16 in Q3 2021.
- Asymmetry Capital Management's portfolio value rose 14% quarter-over-quarter to $166M.
Based on Asymmetry Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.